The differential diagnosis of perineal biopsies can include squamous intraepithelial lesions, extramammary Paget's disease, and melanoma. Less frequently two of these lesions coexist. BD ProExtC is a recently developed immunoassay that targets expression of two genes shown to be associated with cervical cancer. Immunostaining for ProExtC has been validated in cervical cytology and positive staining has also been shown to be strongly associated with human papilloma virus (HPV)-induced cervical and anal intraepithelial neoplasia in biopsies. We observed positive staining for ProExtC in Paget cells in all of 26 cases of Paget's disease irrespective of tissue site (extramammary, mammary) and in melanoma cells in all of 12 cases of primary perineal melanoma with immunostaining in 450% of malignant cells in 73% of Paget disease cases and 43% of perineal melanoma cases. Positive staining was heterogeneous and exclusively nuclear in all cases. In situ hybridization was negative for low-risk and high-risk HPV subtypes in all Paget and melanoma cases that were tested. Currently neither of these lesions is known to be HPV related although according to the literature the possibility of a role for HPV in melanoma is still unsettled. Relevant literature is reviewed.
BD ProExtC is a recently developed immunoassay that targets the expression of minichromosome maintenance protein 2 (MCM2) and topoisomerase II-a (TOP2A), two genes shown by microarray analysis to be associated with cervical carcinoma. ProExtC has been validated in cervical cytology 1 and Kelly et al 2 have suggested that ProExtC may be useful in the diagnosis of high-grade squamous intraepithelial lesions in cervical cytology. Anal epithelium, similar to cervical epithelium, has a proclivity for human papilloma virus (HPV) infection and high-risk serotypes of HPV have been shown to be involved in the pathogenesis of cervical and anal squamous carcinomas and their precursor lesions. We have recently shown that ProExtC staining is strongly associated with HPV-induced cervical and anal squamous intraepithelial lesions. 3, 4 In selected cases, the differential diagnosis of squamous intraepithelial lesion in the perineum can include extramammary Paget's disease and melanoma. Infrequently two of these lesions occur together. We encountered an anal biopsy that exhibited positive staining for ProExtC in Paget cells and in the coexistent anal intraepithelial neoplasia (AIN). Hence, this study was designed to assess immunostaining for ProExtC in extramammary Paget's disease and perineal melanoma.
Materials and methods
After IRB approval, 26 cases of Paget's disease (7 perianal, 11 vulvar, 8 mammary) and 12 cases of primary perineal melanoma (1 vaginal, 7 vulvar, 4 anorectal) were retrieved from our files. In most cases, one or more additional stains (CEA, cytokeratin 7, mucicarmine, S100, HMB45, melan A) had been performed before sign-out for confirmation of diagnoses. Patients ranged in age from 40 to 87 years. Thirty-five (92% of the Paget's and 92% of the melanomas) of the lesions occurred in women. Three of the lesions (two perianal Paget's, one anal melanoma) occurred in men. Invasive tumor was present in eight (31%) of the Paget and ten (83%) of the melanoma cases. 
Results

Immunostaining for ProExtC in Paget's Disease
Positive nuclear staining for ProExtC was present in Paget cells in 100% of the cases irrespective of tissue site (Table 1 ; Figures 1-3 ). Staining was heterogeneous and exclusively nuclear with 2-3 þ intensity in each case. In 19 (73%) cases (100% anal, 45% vulvar, 88% mammary), 50% or more of the Paget cells stained positive. In some cases, variable numbers of benign squamous cells in the basal layers also stained positive. When present in the section associated invasive adenocarcinomas (two anal, three vulvar, two mammary) and ductal carcinoma-in situ also stained positive for ProExtC to approximately the same extent as the Paget cells. In situ hybridization was negative for low-risk and high-risk HPV subtypes in all of the extramammary Paget's disease cases that were tested (seven anal and five vulvar each with positive staining for ProExtC in 50% or more Paget cells; three vulvar each with positive staining for ProExtC in 25-50% Paget cells) including one anal Paget's with PCR positive for HPV 16 and ProExtC positivity in 475% of Paget cells (Figures 1-3 ).
Immunostaining for ProExtC in Perineal Melanoma
Positive nuclear staining for ProExtC was present in melanoma cells in 100% of the cases irrespective of tissue site (Table 2; Figure 4 ). Staining was heterogeneous and exclusively nuclear. The percentage of melanoma cells that stained varied between cases and from microscopic field to field within some cases. In five (42%) of the perineal melanomas (100% anorectal, 14% vulvar), 50% or more of the melanoma cells in at least one tumor field in the section stained positive. In one polypoid/nodular anorectal melanoma, the percentage of melanoma cells that stained positive for ProExtC ranged from o10 to 490% and intensity of staining ranged from 1 þ to 3 þ . As in the Paget cases, variable numbers of benign squamous cells in the basal layers also stained positive. Neither the extent nor the intensity of staining for ProExtC correlated with the presence of or depth of invasive tumor. In situ hybridization was negative for low-risk and high-risk HPV subtypes in all of the perineal melanomas that were tested (three anorectal and one vulvar each with positive staining for ProExtC in 50% or more melanoma cells and one anorectal in which o10 to 490% of melanoma cells stained positive for ProExtC depending on the microscopic field selected) (Table 2; Figure 4 ).
Discussion
The incidence of anal squamous carcinoma and its precursor dysplastic lesions is increasing. 6, 7 Although anal cytology is useful for screening individuals at high risk for HPV-associated AIN, biopsy remains the gold standard for diagnosis and treatment. In selected cases, the differential diagnosis of HPV-induced squamous intraepithelial lesions in the perineum (AIN, VIN, VAIN) can include extramammary Paget's disease (an intrae- pithelial proliferation of glandular-type cells) 8 and/ or superficial spreading melanoma (an intraepithelial proliferation of atypical melanocytic cells). Infrequently, these lesions can coexist. [8] [9] [10] [11] ProExtC is a recently developed assay that has been shown to be useful in the diagnosis of HPVassociated squamous intraepithelial lesions involving anogenital epithelium but has not yet been widely utilized. Strong nuclear staining for ProExtC was seen in 450% of lesional cells in 48% of HPVassociated low-grade cervical intraepithelial neoplasia, 48% of low-grade AIN, 92% of high-grade CIN, and 70% of high-grade AIN. 3, 4 Positive staining in 450% of cells correlated strongly with presence of HPV DNA as determined by in situ hybridization in both cervical and anal lesions. In the current study, we observed immunoreactivity for ProExtC in all cases of extramammary Paget's disease and perineal malignant melanoma with strong immunostaining in 450% of malignant cells in most (73%) cases of Paget's disease and 43% of perineal melanoma cases, findings not previously reported. Although 50% of our cases of AIN and CIN showed HPV by in situ hybridization, no HPV was detected by in situ hybridization in the cases of Paget's disease and melanoma. In situ hybridization, although a specific test, is known to lack sensitivity. Currently neither of these lesions is known to be HPV related, but according to the literature the possibility of a role for HPV in melanoma is still unsettled.
In situ hybridization studies for low-risk and high-risk HPV DNA have uniformly failed to detect the presence of HPV in extramammary Paget's disease, although viral DNA has been identified in the coexistent HPV-associated lesions (low-risk HPV DNA in the condylomatous component of a scrotal Paget's disease, high-risk HPV DNA in coexistent Bowen's disease of the scrotum, and high-risk HPV DNA in coexistent squamous carcinoma of the vulva. 8, 9, [12] [13] [14] PCR studies for HPV have also been reported as negative in all mammary and extramammary Paget's disease (20/20 and 14/14 cases, respectively). 15, 16 Although most of our cases of anal Paget's disease were positive for ProExtC, HPV type 16 was detected by PCR in one case where 75% of Paget cells stained positive. This case did not show histologic changes diagnostic of HPV nor was HPV DNA detected by in situ hybridization. Thus, it appears that the immunostaining for ProExtC observed in Paget's disease might be unrelated to HPV. The etiology of malignant melanoma is unknown. The possibility of HPV as an etiologic agent or as a coinfector with or without a role in tumor promotion has been queried for cutaneous as well as anogenital melanoma. Although a few studies have reported the presence of HPV type 16 in melanoma, [17] [18] [19] [20] most studies have reported the presence of epidermodysplasia verruciformis/cutaneous HPV DNA. In 1986, Scheurlen et al 21 reported the presence of a specific DNA sequence corresponding to HPV subtype 38 in a superficial spreading melanoma of an immunosuppressed patient. HPV 38 has been associated with some cases of epidermodysplasia verruciformis and is not currently considered a genital mucosal HPV. 17 Takamiyagi et al 18 reported HPV 16 DNA in a malignant melanoma that had developed as a result of rapid coalescence of papular and nodular pigmented tumors on the leg of a 37-year-old woman and Roussaki-Schulze et al 19 reported HPV type 16 DNA in two of 20 cutaneous melanomas. In a study of cutaneous melanomas, Dreau et al 22 found that the HPV-positive melanomas grew better in tissue culture and were associated with recurrences and clinically aggressive tumors whereas the HPVnegative melanomas failed to grow in tissue culture and the corresponding patients remained alive and free of tumor recurrence. They suggested that HPV might have a role as a cofactor in the development of melanoma and might 'modulate a more aggressive phenotype' in HPV-containing melanoma. Rohwedder et al 17 reported DNA for multiple HPV subtypes including HPV 16 in two vulvar melanomas and surrounding skin (one with lichen sclerosus and one with pigmented vulvar squamous papillomatosis) and suggested that the presence of DNA of multiple HPV types and of integrated HPV DNA in skin associated with vulvar melanomas might indicate a direct or indirect role for HPV in the development of melanoma. In a subsequent study, 23 they also identified HPV DNA in six of nine vulvovaginal melanomas. Only nongenital-mucosal HPV subtypes were identified; type specific probes for HPV 16 were negative. Dahlgren et al 24 evaluated 35 primary melanomas in non-sun exposed areas utilizing a protocol that they describe as highly sensitive for identification of DNA sequences from 36 HPV subtypes including HPV 16 and concluded that HPV is rarely detected in primary melanomas of non-sun exposed areas. Using a PCR-enzyme-linked immunosorbent assay, La Placa et al 25 detected mucosal high-risk HPV DNA in 27% of 51 primary melanomas and in 24% of acquired dysplastic melanocytic nevi, which they considered as precursor lesions for melanoma. Utilizing a combination of fluorescent in situ hybridization and chemiluminescent immunohistochemistry, Ambretti et al 20 recently reported colocalization of high-risk HPV (HPV 16 and 18) nucleic acids and HMB45 (a melanoma marker) in melanoma cells, which they interpreted as supportive of a possible active role for HPV in malignant melanoma. The plethora of HPV subtypes (currently more than 100), cross-reactivity for HPV antigens, and limited specificity and sensitivity of various testing modalities have no doubt contributed to the complexity of this issue. Thus at this time, the role of HPV in melanoma remains controversial. ProExtC staining in melanoma cells could be indirect evidence in support of a role for HPV or could represent nonspecific staining similar to that observed in extramammary Paget's disease.
Successful application of an immunostain requires awareness of its staining spectrum. Our findings suggest that immunostaining for ProExtC has a limited role for the diagnosis of squamous intraepithelial lesions when extramammary Paget's disease and/or melanoma are in the differential diagnosis. TOP2A (a topoisomerase) and MCM2 (a helicase) are both involved in DNA replication during the G 1 to S-phase of the cell cycle. High-risk HPV infection provides one but not the only mechanism that can result in aberrant S-phase induction (premature and prolonged entry into the S-phase) manifesting as overexpression of these proteins. Hence, ProExtC positivity is not equivalent to the presence of high-risk HPV. 
